Multiple myeloma with CD138 changed from positive to negative: A case report

被引:1
作者
Yu, Jianlin [1 ]
Tan, Liming [1 ]
Wu, Qiong [1 ]
Rao, Yanfei [1 ]
Ao, Jianyun [1 ]
Yang, Weiming [1 ]
Zou, Bei [1 ]
Chen, Juanjuan [1 ]
机构
[1] Nanchang Univ, Affiliated Hosp 2, Dept Clin Lab, Jiangxi Prov Key Lab,Lab Med, Nanchang 330006, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
CD138; flow cytometry; multiple myeloma; CELLS; SURVIVAL;
D O I
10.1002/cyto.b.21869
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background Multiple myeloma (MM) is a common malignant disease of the blood system, caused by the neoplastic proliferation of plasma cells that accumulate in bone marrow (BM). Here, we report a case of MM patient with CD138 marker changed from positive to negative. Methods BM and peripheral blood samples from a 48-year-old patient with MM were examined and analyzed by conventional morphology, flow cytometry, and immunodetection. Results Imaging examination and clinical manifestations fulfilled criteria for MM. On the first hospitalization, flow cytometry showed that the cells were CD138(+)/CD38(+)/CD19(-)/CD56(+). However, on the fifth hospitalization, flow cytometry revealed that the cells were CD138(-)/CD38(+)/CD19(-)/CD56(+). Conclusions MM is diagnosed on imaging and clinical manifestations, immunophenotype of flow cytometry is also an important method of diagnosing MM. However, the discovery of atypical immunophenotypes cannot prevent the diagnosis of MM, even provide a clue of disease progression.
引用
收藏
页码:249 / 253
页数:5
相关论文
共 50 条
  • [1] CD138 Negative Plasma Cells in Relapsed CNS Multiple Myeloma
    Neha Singh
    Jatin S. Gandhi
    Narendra Agrawal
    Ajit Panaych
    Narender Tejwani
    Anurag Mehta
    Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 630 - 632
  • [2] CD138 Negative Plasma Cells in Relapsed CNS Multiple Myeloma
    Singh, Neha
    Gandhi, Jatin S.
    Agrawal, Narendra
    Panaych, Ajit
    Tejwani, Narender
    Mehta, Anurag
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2017, 33 (04) : 630 - 632
  • [3] Characterization of potential CD138 negative myeloma "stem cells"
    Christensen, Jacob H.
    Jensen, Pia V.
    Kristensen, Ida B.
    Abildgaard, Niels
    Lodahl, Marianne
    Rasmussen, Thomas
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (06): : E18 - E20
  • [4] The research on the CD138 immune magnetic beads for multiple myeloma cells sorting
    Zhang, Jijun
    Ma, Xuemei
    2009 3RD INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICAL ENGINEERING, VOLS 1-11, 2009, : 1755 - 1756
  • [5] In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
    Omstead, David T.
    Mejia, Franklin
    Sjoerdsma, Jenna
    Kim, Baksun
    Shin, Jaeho
    Khan, Sabrina
    Wu, Junmin
    Kiziltepe, Tanyel
    Littlepage, Laurie E.
    Bilgicer, Basar
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [6] Profilin 1 induces drug resistance by downregulating CD138 expression via autophagy in multiple myeloma
    Wang, Ya
    Dai, Ziyu
    Xiao, Shengying
    Zeng, Furen
    Lu, Yichen
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [7] Vascular endothelial growth factor receptor 3 is a novel marker differing CD138-positive and CD138-negative multiple myeloma cells
    Kostjukova, Maria N.
    Tupitsyn, Nikolai N.
    Karamysheva, Aida F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (06) : 840 - 843
  • [8] Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
    Kawano, Yawara
    Fujiwara, Shiho
    Wada, Naoko
    Izaki, Mikiko
    Yuki, Hiromichi
    Okuno, Yutaka
    Iyama, Kenichi
    Yamasaki, Hiroshi
    Sakai, Akira
    Mitsuya, Hiroaki
    Hata, Hiroyuki
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (03) : 876 - 884
  • [9] Effect of levamisole on expression of CD138 and interleukin-6 in human multiple myeloma cell lines
    Nageshwari, B.
    Merugu, Ramchander
    INDIAN JOURNAL OF CANCER, 2017, 54 (03) : 566 - 571
  • [10] In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
    David T. Omstead
    Franklin Mejia
    Jenna Sjoerdsma
    Baksun Kim
    Jaeho Shin
    Sabrina Khan
    Junmin Wu
    Tanyel Kiziltepe
    Laurie E. Littlepage
    Basar Bilgicer
    Journal of Hematology & Oncology, 13